[
  {
    "ts": null,
    "headline": "Bernstein Raises Reddit (RDDT) PT to $190, Cites Digital Ad Space, AI’s Role",
    "summary": "Reddit Inc. (NYSE:RDDT) is one of the best up and coming stocks to buy right now. On October 22, Bernstein analyst Mark Shmulik raised the firm’s price target on Reddit to $190 from $185 and kept a Market Perform rating, as there are no shorts in the digital ad space that the firm sees in […]",
    "url": "https://finnhub.io/api/news?id=af5a17838494329936b1413ecfbf5a8ae5fc310fe254b64eb6411e54395fcbae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832626,
      "headline": "Bernstein Raises Reddit (RDDT) PT to $190, Cites Digital Ad Space, AI’s Role",
      "id": 137266897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Reddit Inc. (NYSE:RDDT) is one of the best up and coming stocks to buy right now. On October 22, Bernstein analyst Mark Shmulik raised the firm’s price target on Reddit to $190 from $185 and kept a Market Perform rating, as there are no shorts in the digital ad space that the firm sees in […]",
      "url": "https://finnhub.io/api/news?id=af5a17838494329936b1413ecfbf5a8ae5fc310fe254b64eb6411e54395fcbae"
    }
  },
  {
    "ts": null,
    "headline": "Truist Lowers Toast (TOST) PT to $47 Ahead of Q3 FinTech Earnings",
    "summary": "Toast Inc. (NYSE:TOST) is one of the best up and coming stocks to buy right now. On October 24, Truist analyst Matthew Coad lowered the firm’s price target on Toast to $47 from $51 with a Buy rating on the shares. This sentiment was announced as part of the firm’s broader research note that previewed […]",
    "url": "https://finnhub.io/api/news?id=0c01209e5b342021bb8357f19d0581258829edf00ef5fe1e97f9cee943c75642",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832620,
      "headline": "Truist Lowers Toast (TOST) PT to $47 Ahead of Q3 FinTech Earnings",
      "id": 137266898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Toast Inc. (NYSE:TOST) is one of the best up and coming stocks to buy right now. On October 24, Truist analyst Matthew Coad lowered the firm’s price target on Toast to $47 from $51 with a Buy rating on the shares. This sentiment was announced as part of the firm’s broader research note that previewed […]",
      "url": "https://finnhub.io/api/news?id=0c01209e5b342021bb8357f19d0581258829edf00ef5fe1e97f9cee943c75642"
    }
  },
  {
    "ts": null,
    "headline": "Mizuho Lowers Fiserv (FI) PT to $145 Due to Concerns Over Optimistic Sales Guidance.",
    "summary": "Fiserv Inc. (NYSE:FI) is one of the most undervalued large cap stocks to buy right now. On October 28, Mizuho lowered the price target on Fiserv to $145 from $165 and kept an Outperform rating on the shares as part of an earnings preview. The firm considers the company’s organic sales guidance for Q3 2025 […]",
    "url": "https://finnhub.io/api/news?id=1c48e8e601edbe2d8407802276effdce1b5056165fc024ed15a52a5a0b06ebac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832613,
      "headline": "Mizuho Lowers Fiserv (FI) PT to $145 Due to Concerns Over Optimistic Sales Guidance.",
      "id": 137266844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Fiserv Inc. (NYSE:FI) is one of the most undervalued large cap stocks to buy right now. On October 28, Mizuho lowered the price target on Fiserv to $145 from $165 and kept an Outperform rating on the shares as part of an earnings preview. The firm considers the company’s organic sales guidance for Q3 2025 […]",
      "url": "https://finnhub.io/api/news?id=1c48e8e601edbe2d8407802276effdce1b5056165fc024ed15a52a5a0b06ebac"
    }
  },
  {
    "ts": null,
    "headline": "Meta downgraded, Coinbase upgraded: Wall Street's top analyst calls",
    "summary": "Meta downgraded, Coinbase upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=567230222ecc56c5183d54b68e5872f9cf97d62e137b972b97241bb4a8bd87cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831602,
      "headline": "Meta downgraded, Coinbase upgraded: Wall Street's top analyst calls",
      "id": 137266417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Meta downgraded, Coinbase upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=567230222ecc56c5183d54b68e5872f9cf97d62e137b972b97241bb4a8bd87cd"
    }
  },
  {
    "ts": null,
    "headline": "Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating",
    "summary": "DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 with a Buy rating on the shares as part of the firm’s broader research note previewing Q3 2025 results […]",
    "url": "https://finnhub.io/api/news?id=e82a7cb804f5d9c707003167158272e9b53fd7e636e4914960c4aaa495d4d400",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831065,
      "headline": "Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating",
      "id": 137266901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 with a Buy rating on the shares as part of the firm’s broader research note previewing Q3 2025 results […]",
      "url": "https://finnhub.io/api/news?id=e82a7cb804f5d9c707003167158272e9b53fd7e636e4914960c4aaa495d4d400"
    }
  },
  {
    "ts": null,
    "headline": "Truist Financial Maintains a Buy Rating on Minerals Technologies (MTX)",
    "summary": "Minerals Technologies Inc. (NYSE:MTX) is one of the most undervalued small cap stocks to invest in now. Truist Financial analyst Pete Osterland reiterated a Buy rating on Minerals Technologies Inc. (NYSE:MTX) on October 24, setting an $84 price target. The rating update came after the company reported its fiscal Q3 2025 results on October 23, […]",
    "url": "https://finnhub.io/api/news?id=60e51b83b633404ce0b9393a09b986320041a7e7581d30ffaa83c321d09b2f3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761829715,
      "headline": "Truist Financial Maintains a Buy Rating on Minerals Technologies (MTX)",
      "id": 137266902,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Minerals Technologies Inc. (NYSE:MTX) is one of the most undervalued small cap stocks to invest in now. Truist Financial analyst Pete Osterland reiterated a Buy rating on Minerals Technologies Inc. (NYSE:MTX) on October 24, setting an $84 price target. The rating update came after the company reported its fiscal Q3 2025 results on October 23, […]",
      "url": "https://finnhub.io/api/news?id=60e51b83b633404ce0b9393a09b986320041a7e7581d30ffaa83c321d09b2f3f"
    }
  },
  {
    "ts": null,
    "headline": "Solid Biosciences to Participate at Upcoming Investor Conferences",
    "summary": "CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Truist Securities BioPharma SymposiumDr. Gabriel Brooks, Chief Medical Officer, will participate in a panel discussion titled “Precision Medicine: DMD, FA, and Beyond” on Thursday, November 6, 2025, at 1",
    "url": "https://finnhub.io/api/news?id=4f7d1a001c3626f5fcb3cc1b5f2d05bbf94de76585e036c0c819638ce7d66150",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825600,
      "headline": "Solid Biosciences to Participate at Upcoming Investor Conferences",
      "id": 137266903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Truist Securities BioPharma SymposiumDr. Gabriel Brooks, Chief Medical Officer, will participate in a panel discussion titled “Precision Medicine: DMD, FA, and Beyond” on Thursday, November 6, 2025, at 1",
      "url": "https://finnhub.io/api/news?id=4f7d1a001c3626f5fcb3cc1b5f2d05bbf94de76585e036c0c819638ce7d66150"
    }
  },
  {
    "ts": null,
    "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
    "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
    "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825089,
      "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
      "id": 137267929,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "TFC",
      "source": "SeekingAlpha",
      "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
      "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d"
    }
  },
  {
    "ts": null,
    "headline": "Tracking the Evolving Narrative for Booking Holdings Amid Analyst Shifts and New Partnerships",
    "summary": "Booking Holdings’ fair value estimate has recently been adjusted upward from $6,100 to $6,140, reflecting growing analyst optimism. This modest increase is supported by a slightly lower discount rate and higher revenue growth assumptions, indicating renewed confidence in the company’s forward trajectory. Stay tuned to discover how evolving analyst perspectives can help investors track the changing narrative around Booking Holdings over time. Stay updated as the Fair Value for Booking Holdings...",
    "url": "https://finnhub.io/api/news?id=5c74a36aeb83963e4638f7e51f8f3bcea52584d2d0ba8cb05c39fca74b280b19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761798657,
      "headline": "Tracking the Evolving Narrative for Booking Holdings Amid Analyst Shifts and New Partnerships",
      "id": 137263716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Booking Holdings’ fair value estimate has recently been adjusted upward from $6,100 to $6,140, reflecting growing analyst optimism. This modest increase is supported by a slightly lower discount rate and higher revenue growth assumptions, indicating renewed confidence in the company’s forward trajectory. Stay tuned to discover how evolving analyst perspectives can help investors track the changing narrative around Booking Holdings over time. Stay updated as the Fair Value for Booking Holdings...",
      "url": "https://finnhub.io/api/news?id=5c74a36aeb83963e4638f7e51f8f3bcea52584d2d0ba8cb05c39fca74b280b19"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Around HCA Healthcare Is Evolving After Earnings and Analyst Upgrades",
    "summary": "HCA Healthcare’s stock narrative has shifted, following a significant increase in its fair value estimate from $417.52 to $471.00. This revised price target reflects renewed optimism about the company’s performance and future outlook, while the discount rate remains steady at 6.78%. Stay tuned to learn how you can keep up with these evolving expectations and the key drivers that shape them. What Wall Street Has Been Saying Analyst commentary following HCA Healthcare’s recent earnings has been...",
    "url": "https://finnhub.io/api/news?id=1de69b56c824247db69f1d231615a41f920788519369117e71bc46c06e45472d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761783246,
      "headline": "How the Narrative Around HCA Healthcare Is Evolving After Earnings and Analyst Upgrades",
      "id": 137263790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "HCA Healthcare’s stock narrative has shifted, following a significant increase in its fair value estimate from $417.52 to $471.00. This revised price target reflects renewed optimism about the company’s performance and future outlook, while the discount rate remains steady at 6.78%. Stay tuned to learn how you can keep up with these evolving expectations and the key drivers that shape them. What Wall Street Has Been Saying Analyst commentary following HCA Healthcare’s recent earnings has been...",
      "url": "https://finnhub.io/api/news?id=1de69b56c824247db69f1d231615a41f920788519369117e71bc46c06e45472d"
    }
  }
]